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Genetic and proteomic analysis of human tumor samples can provide an important compliment to 
information obtained from model systems. Here we examined protein and gene expression from the 
Cancer Genome and Proteome Atlases (TCGA and TCPA) to characterize proteins and protein-coding 
genes that are selectively upregulated in KRAS-mutant lung adenocarcinomas. Phosphoprotein 
activation of several MAPK signaling components was considerably stronger in KRAS-mutants than 
any other group of tumors, even those with activating mutations in receptor tyrosine kinases (RTKs) 
and BRAF. Co-occurring mutations in KRAS-mutants were associated with differential activation of 
PDK1 and PKC-alpha. Genes showing strong activation in RNA-seq data included negative regulators 
of RTK/RAF/MAPK signaling along with potential oncogenic effectors including activators of Rac 
and Rho proteins and the receptor protein-tyrosine phosphatase genes PTPRM and PTPRE. These 
results corroborate RAF/MAPK signaling as an important therapeutic target in KRAS-mutant lung 
adenocarcinomas and pinpoint new potential targets.
How mutationally activated KRAS and other canonical RAS genes malignantly transform cells and how to block 
this process for therapeutic benefit has been a subject of intense investigation for over thirty years. The majority 
of efforts to date have relied on model systems, using established cell lines and mouse models. These studies have 
identified signaling pathways that are directly stimulated by biochemically active Ras proteins, including the Raf/
MAPK and PI3K/Akt pathways1. They also have identified pathways or processes further downstream from Ras 
proteins that are involved in malignant phenotypes induced by mutant RAS genes, including the NF-κ B path-
way2,3, transcriptional activity of the oncogene YAP4, generation of reactive oxygen species5, and anabolic glucose 
metabolism6. A third class of proposed oncogenic mediators of mutant RAS genes are induced secreted proteins 
including TGF-α 7, Vegf8, IL-89, IL-610, CXCL111, and CCL512. Several members of these three classes of mediators 
of oncogenic Ras have been explored as potential therapeutic targets but as of yet there hasn’t been a clinically 
successful treatment developed for cancers with mutant RAS genes.
The recent completion of large-scale human cancer sample characterizations such as the Cancer Genome 
Atlas (TCGA) and the Cancer Proteome Atlas (TCPA) has enabled an altogether different approach for discovery 
of protein targets that are upregulated by mutant RAS genes. This approach uses a direct comparison of tumor 
samples containing mutant RAS genes with either corresponding normal tissue samples or with tumor samples 
that contain wild-type RAS genes. One chief advantage of this approach is the analysis is done using the correct 
in vivo physiological context, whereas with model systems there is no guarantee that the physiological context is 
correct although it is thought that mouse models are superior to cell culture models13,14. Another advantage is that 
direct analysis of human cancer takes into account the enormous diversity of co-occurring genomic alterations. 
This diversity requires very large panels of human cancer cell lines to be representative and presents very difficult 
challenges for mouse modeling.
Recently, three discrete subtypes of human KRAS-mutant lung adenocarcinomas were discovered in a break-
through of our understanding of the variability within this type of lung cancer. These three subtypes have both 
distinct RNA expression profiles and different patterns of co-occurring mutations in TP53, STK11, KEAP1, and 
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others15. Furthermore, based on experiments with appropriate cell lines, there appears to be consistent differences 
in responses to HSP90-inhibitors, suggesting that this classification scheme could be useful in guiding treatment 
strategies15.
In this study, we analyzed genomic and proteomic data from human lung adenocarcinomas to examine the 
strength and variability of mutant-KRAS activation of proteins and genes. KRAS-mutants were compared to other 
lung adenocarcinoma samples and were also examined for the effects of commonly co-occurring mutations.
Results
Raf/MAPK signaling proteins are selectively activated in KRAS-mutant lung adenocarcinomas. 
230 lung adenocarcinoma samples have been comprehensively characterized for mutations and gene expression 
by TCGA and these same samples have been characterized by reverse-phase protein array (RPPA) for their levels 
of 160 different proteins and modified proteins16. To determine the selective effects of mutational activation of 
KRAS on these proteins in lung adenocarcinomas, we compared KRAS-mutant tumors (n = 75) to other tumors 
with wild-type KRAS. We further divided tumors with wild-type KRAS into those with other mutations in com-
ponents of the mitogenic RTK/RAF/MAPK pathway and those without, using the criteria found in the TCGA 
publication16. The other activating mutations in the RTK/RAF/MAPK pathway strongly tended toward mutual 
exclusivity and included missense or inframe deletion mutations in EGFR (n = 26), ERBB2 (n = 4), or RIT1 
(n = 5); inactivating mutations in NF1 (n = 19); missense mutations in BRAF (n = 16), MAP2K1 (n = 2), HRAS 
(n = 1), or NRAS (n = 1); exon 14 skipping mutations in MET (n = 10), gene fusions involving ROS1 (n = 4), ALK 
(n = 3), or RET (n = 2); and focal high-level amplification of ERBB2 (n = 5), or MET (n = 5).
We performed pairwise analysis of the three tumor subsets: KRAS mutants, other RTK/RAF/MAPK mutants, 
and all others. Since wanted to examine the differences with the greatest potential biological impact, we ranked 
the differences based on the effect size, rather than p-value which can over emphasize very small changes with 
little variation. We used Cohen’s d statistic that is highly related to the signal-to-noise statistic used in gene 
expression studies17,18. Of all the 160 measured modified proteins and native proteins, the top ranking change 
in KRAS-mutant tumors when compared to either group of wild-type KRAS tumors is activation of MEK1, as 
judged by increased levels detected by the anti-phospho-serine 218,222 MEK1 antibody used by TCPA (Fig. 1A). 
Also top-ranking in both comparisons is phosphorylation activation of MAPK (Fig. 1B) and a direct kinase target 
of MAPK, p90-S6-RSK (Fig. 1C). Significant large effects on activation of other direct kinase targets of MAPK 
(YB-1) and further downstream targets (S6) were also observed (Supplementary Table 1). Also increased in both 
comparisons of KRAS-mutant tumors was activation of mTOR as determined by phosphorylation at serine 2448 
(Fig. 1D). However, both PDK1 and AKT kinases, which might be expected to be upregulated in KRAS-mutant 
lung cancers due to Kras protein interaction with PI3-kinase, did not show any significant phosphorylation acti-
vation in KRAS-mutant tumors (Supplementary Table 1).
Analysis of a well-validated mouse model of KRAS-mutant lung adenocarcinoma revealed that tumors 
showed significant activation of NF-κ b and furthermore that these tumors were dependent upon NF-κ b activity 
for tumor maintenance3. We did not observe any activation of NF-κ b in human KRAS-mutant lung adenocarci-
nomas; in fact, NF-κ b activation was significantly lower in KRAS-mutant tumors compared to other Raf/MAPK 
mutant tumors (Supplementary Table 1).
Other mutations affecting the RTK/RAF/MAPK pathway have specific effects on protein levels. 
We next extended our comparative protein analysis to look within the group with other mutations in the RTK/
RAF/MAPK pathway. The subgroups with sufficiently large numbers for statistical analysis included EGFR 
mutants (n = 26), NF1 mutants (n = 19), MET mutants (n = 15), and BRAF mutants (n = 16). There were sig-
nificant differences (Supplementary Table 2), the most prominent of which are highlighted in Fig. 2. Notably, 
the phosphorylation activation of EGFR and HER2 proteins was significantly higher in EGFR mutants, but there 
was also increased phosphorylation of RET protein and decreased phosphorylation of HER3 and MET proteins 
(Fig. 2). MET mutants on the other hand showed opposite effects, with significant increased phosphorylation 
of MET protein but decreased phosphorylation of EGFR, HER2, and RET (Fig. 2). NF1 mutants also showed 
decreased phosphorylation of EGFR, HER2, and RET proteins (Fig. 2; Supplementary Table 2). We did not 
observe significant effects with these select phosphoproteins in BRAF mutants (Supplementary Table 2).
Effect of co-occurring mutations on protein levels in KRAS-mutant lung adenocarcinomas. 
We next examined the effects of co-occurring mutations in TP53, STK11, and KEAP1 on protein levels in 
mutant-KRAS tumors. Using cBioPortal analysis of TCGA lung adenocarcinomas, we confirmed that mutations 
in TP53 and STK11 tend to be mutually exclusive, whereas mutations in KEAP1 and STK11 tend to co-occur. 
Amongst KRAS-mutant tumors, there were 22 tumors with mutations in TP53 but not STK11 or KEAP1, 20 tum-
ors with mutations in STK11 but not in TP53, and 13 tumors with mutations in KEAP1 but not in TP53 (8 of these 
tumors also had mutations in STK11). There was only one KRAS-mutant tumor with mutations in both TP53 and 
STK11 or KEAP1. Excluding this single sample, we divided KRAS-mutant tumors into three groups: those with 
TP53 mutations (n = 20), those with STK11 and/or KEAP1 mutations (n = 25), and those without any of these 
mutations (n = 27). Pairwise analysis of these three groups revealed that the phosphorylation activation status of 
Raf/MAPK pathway components was not significantly affected (Supplementary Table 3).
The strongest effect of co-occurring TP53 mutations was seen with increased levels of Annexin I protein 
(Fig. 3A). As expected, the group with mutations in the protein kinase gene STK11 had significantly lower lev-
els of activation of its direct target, AMPK, than the other two groups (Fig. 3B). More surprising however were 
the significantly lower levels of phosphorylation activated PDK1 and PKC-alpha proteins in this same group 
(Fig. 3C,D).
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Figure 1. Relative levels of select phosphoproteins in three subgroups of human lung adenocarcinomas. All 
values are plotted on an arbitrary log2 scale to highlight relative levels rather than absolute amounts. For each 
panel, the red colored group represents KRAS-mutant tumors, the orange colored group represents other Raf/
MAPK pathway mutants, and the blue colored group represents all other tumors. Brackets with associated p-
values indicate significant differences. (A) levels of MEK1_pS217_S221; (B) levels of MAPK_pT202_Y204;  
(C) levels of p90RSK_pT359_S363; (D) levels of mTOR_pS2448.
Figure 2. Relative levels of select phosphoproteins within KRAS-wild type lung adenocarcinomas with 
other mutations in the RTK/RAF/MAPK pathway. Pairwise comparisons were made between EGFR mutants 
(n = 29) and all other mutants (n = 71); NF1 mutants (n = 19) and all other mutants (n = 81); MET mutants 
(n = 15) and all other mutants (n = 85).
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Top ranked KRAS-mutant induced genes by RNA-seq data. We then looked at RNA-seq data to find 
genes with the greatest induction specifically in KRAS-mutant lung adenocarcinomas. We ranked genes based 
on the average effect size when KRAS-mutant tumors were compared to tumors with other mutations in genes of 
the Raf/MAPK pathway, and when compared to tumors with no mutations in genes of the Raf/MAPK pathway. 
KRAS itself was the top-ranked induced gene (Fig. 4; Supplementary Table 4). Within the top-100 induced genes 
were five negative regulators of RTK/MAPK signaling (DUSP4, DUSP6, NF1, SPRED2, SPRY4); the canonical Raf/
MAPK transcriptional targets ETV4 and ETV5 (ETS-family members) and FOS (Fig. 4; Supplementary Table 4). 
Also within this top-ranked group are several candidate transcriptional oncogenic effectors for mutant KRAS, 
including the receptor tyrosine kinase genes INSR and IGFR1; the receptor tyrosine phosphatase genes PTPRE 
and PTPRM; and genes encoding guanine-nucleotide exchange-factors that activate Rac/Rho/Cdc42 proteins 
DOCK5, DOCK1, DNMBP, and PLEKHG2; (Fig. 4). Also included in the top-100 ranked induced genes is the 
gene CXorf61 which encodes a tumor antigen termed Kita-Kyushu lung cancer antigen 1 (Fig. 4).
Approximately 50% of the aforementioned genes that are selectively induced in KRAS-mutant lung adenocar-
cinomas were also significantly affected by co-occurring mutations in TP53, STK11, or KEAP1. For the most part, 
co-occurring mutations in STK11 and/or KEAP1 were associated with significantly stronger expression of these 
genes. In only one case (DUSP6) was co-occurrence of mutant TP53 associated with stronger expression (Fig. 5).
Discussion
Several components of the Raf/MAPK pathway show strong selective activation in KRAS-mutant lung adeno-
carcinomas, providing further corroboration that this pathway is a key therapeutic target for KRAS-mutant lung 
tumors. However, a potentially important finding of this study is that many of the signaling proteins and pathways 
thought to be activated in KRAS-mutant human lung adenocarcinomas based on studies with models systems 
Figure 3. Relative levels of select proteins phosphoproteins in three subgroups of KRAS-mutant 
adenocarcinomas. All values are plotted on an arbitrary log2 scale to highlight relative levels rather than 
absolute amounts. For each panel, the green colored group represents KRAS/TP53 double-mutant tumors, 
the violet colored group represents other KRAS/STK11, KRAS/KEAP1, and KRAS/STK11/KEAP1 compound 
mutants, and the brown colored groups KRAS mutants without those other mutations. Brackets with associated 
p-values indicate significant differences. (A) levels of Annexin I; (B) levels of AMPK_pT172-R; (C) levels of 
PDK1_pS241; (D) levels of PKC-alpha_pS657.
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are not activated, at least not at steady state levels as assayed by immunoblotting of tissue samples. This makes it 
less likely that these pathways or proteins correspond to KRAS-selective dependencies. These proteins include 
PI3-kinase (as judged by activation of AKT), AKT, and NF-κ B, all of which have been proposed to be important 
mediators of mutant KRAS in lung adenocarcinomas3,19. Since mTOR is the only component of the PI3-kinase 
pathway that was selectively activated in KRAS-mutant tumors, a greater therapeutic window could conceiva-
bly be achieved by combining Raf/MAPK inhibitors with highly selective mTOR inhibitors that do not inhibit 
PI3-kinase.
All three subtypes of KRAS-mutants showed approximately equivalent activation of Raf/MAPK components. 
However, there were significant differences in protein and phosphoprotein levels detected in the three subgroups. 
The subgroup comprised of KRAS/STK11 and KRAS/KEAP1 double mutants, along with KRAS/STK11/KEAP1 
triple mutants, had significantly lowers levels of phosphorylated AMPK, which is to be expected since AMPK is 
a direct kinase target of STK11. However this group was more unexpectedly associated with lower levels of phos-
phorylation activation of PDK1 and PKC-alpha, both of which have been actively pursued targets for developing 
potentially clinically effective inhibitors. However in this case, it would appear that loss of STK11 function is likely 
driving this decrease in activity, and that as such this would not represent a potential selective dependency in any 
of the KRAS-mutant subgroups.
Genomic studies usually rank differentially expressed genes by p-value or FDR. However, this ranking 
method does not taking into account the size of the effect. Potential transcriptional effectors of mutant-KRAS 
Figure 4. Heatmap showing the relative RNA values of select genes in three subgroups of human lung 
adenocarcinomas. The three subgroups include KRAS-mutant tumors, other Raf/MAPK pathway mutants, 
and all other tumors. The select genes are indicated on the right. Row values were normalized and scaled and 
presented as Z-scores.
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would more likely be genes showing the largest consistent increase in RNA. Therefore we used Cohen’s d 
statistic, closely related to the signal-to-noise statistic, to rank genes selectively upregulated in KRAS-mutant 
tumors. Amongst the top 100 upregulated genes were several negative regulators of Raf/MAPK signaling, con-
sistent with an important known aspect of negative feedback regulation in this pathway20,21, as well as canon-
ical transcriptional targets for Raf/MAPK signaling including FOS and the ETS-family members ETV4 and 
ETV5. Additionally, several potential oncogenic transcriptionally activated targets were uncovered including 
IGF1R and INSR. A connection between mutant KRAS and IGF1R in lung adenocarcionoma has previously 
been documented22. We detected transcriptional activation of several guanine-nucleotide exchange factors 
that activate different proteins in the Rac/Rho/Cdc42 family. Thus the effect of mutational activation of KRAS 
on guanine-nucleotide exchange factors for small GTP-binding proteins is broader in lung adenocarcinoma 
than its biochemical activation of exchange factors that activate Ral proteins. Upregulation of the receptor 
protein-tyrosine phosphatase gene PTPRE, the third highest ranked upregulated gene, is of particular interest 
since it has been shown to be upregulated by RAS in a mouse model of mammary carcinoma and to possess on 
its own the ability to promote mammary tumor formation23,24. Finally, this set of upregulated genes includes a 
potential immunotherapy target for KRAS-mutant lung adenocarcinomas, the Kita-Kyushu lung cancer anti-
gen 1, encoded by the CXorf61 gene25. This protein has also been shown to be a potential target for T cell based 
therapies in triple-negative breast cancer26.
Methods
We used mutational, RNAseq and protein data in our analysis from the TCGA lung adenocarcinoma project. 
All data downloaded was Level 3. Mutation data was downloaded from cBioPortal for Cancer Genomics (www.
cbioportal.org), under Lung Adenocarcinoma (TCGA, Provisional) with “All Complete Tumors (230)”. RNAseq 
data was downloaded from FireBrowse by Broad Institute (www.firebrowse.org), choosing “illuminahiseq_
rnaseqv2-RSEM_genes”. Protein data was downloaded from The Cancer Proteome Atlas (TCPA) project in MD 
Anderson Cancer Center (bioinformatics.mdanderson.org/main/TCPA). To generate heatmaps, the R package 
“gplots” was used.
We segregated samples using cBioPortal into three mutually exclusive groups: ones with KRAS missense muta-
tions, ones with mutations in genes encoding other components of the RTK/RAF/MAPK pathway as delineated 
in the text, and other samples. Those three subgroups were used to perform pairwise comparisons using protein 
(RPPA) and RNAseq data. We used Cohen’s d to measure effect size using the R-package “effsize”. Ranking with 
both effect size and t-test p-value generated top-ranked proteins and genes induced in KRAS mutants or Raf/
MAPK pathway mutants (Fig. 1, Supplementary Table 1). We used a similar approach to divide KRAS mutants 
into three groups depending on TP53, STK11, or KEAP1 status.
Figure 5. Heatmap showing the relative RNA values of select genes in three subgroups of KRAS-mutant 
human lung adenocarcinomas. The three subgroups are KRAS/TP53 double mutants; KRAS/STK11, KRAS/
KEAP1, and KRAS/STK11/KEAP1 compound mutants; and KRAS mutants without those other mutations. The 
select genes are indicated on the right. Row values were normalized and scaled and presented as Z-scores.
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